Clinical Report: FDA Approves New Treatment for Thyroid Eye Disease
Overview
The FDA has approved veligrotug-vvze (Lumvoa) for thyroid eye disease (TED), applicable to patients regardless of disease activity or duration. The approval follows positive results from the phase 3 THRIVE trials, which demonstrated significant improvements in proptosis and diplopia.
Background
Thyroid eye disease is an autoimmune condition that leads to inflammation and remodeling of tissues around the eyes, causing symptoms such as proptosis and diplopia. Effective treatment options are crucial for managing the disease's impact. The recent approval of Lumvoa is based on findings from the THRIVE trials.
Data Highlights
Trial
Endpoints Met
Infusion Schedule
Proptosis Reduction
THRIVE
Primary and Secondary
5 infusions every 3 weeks
As early as 3 weeks
THRIVE-2
Primary and Secondary
5 infusions every 3 weeks
As early as 3 weeks
Key Findings
FDA approved veligrotug-vvze (Lumvoa) for TED treatment.
Approval includes patients with both active and chronic disease.
Phase 3 THRIVE trials showed significant reductions in proptosis and improvements in diplopia.
Infusion reactions occurred in approximately 9% of patients.
Common adverse reactions included muscle spasms, headache, and hyperglycemia.
ViridianCares program offers support for patient access and financial assistance.
Clinical Implications
Healthcare providers should consider Lumvoa as a treatment option for patients with thyroid eye disease, particularly those with active symptoms. Monitoring for potential adverse reactions, especially in patients with preexisting conditions, is essential.
Conclusion
The approval of Lumvoa marks a significant development in the management of thyroid eye disease, providing a new treatment avenue for affected patients.
In a pooled analysis of more than 1.5 million patients, sugar-sweetened beverages were associated with higher risks of HCC and ICC, while artificially-sweetened beverages showed no independent association with hepatic cancer.
